| Background and objectiveH.pylori (Helicobacter pylori) is generally accepted to be the major etiologic agent for gastritis and peptic ulcer disease as well as for gastric adenocarcinoma and lymphoma of MALT (Mucosal Associated Lymphoid Tissue) , and has therefore been designated as a class I carcinogen by the World Health Organization. More than 50% of the human population worldwide are infected with H.pylori and this bacterium is now recognized as the most widespread human pathogen. Current antibiotic-based triple therapies are not practical for global control due to the high cost, problems with patients' compliance, the emergence of antibiotic-resistant strains and disorder of intestinal flora. Further more, there is a controversy on antibiotic-based therapies to asymptomatic and children patients, which share the large proportion of the infected population . Vaccination of humans against H.pylori infection could be an effective and economic approach to control this pathogen. Various H.pylori antigens , such as whole bacterial cell sonicates and recombinant subunit proteins, have been prepared for experimental vaccines and several immune projects were designed. However, most vaccines need strong mucosal adjuvant, such as CT and LT, to induce protective immune because of their poor immunogenicity.CT and LT can not be given to humans due to its toxicity. The Live...
|
PDF Full Text Request